Publications

Publication: PLoS One

Holt R, Upadhyay J, Smith P, Allison C, Baron-Cohen S, Chakrabarti B.

27 July 2018

Publication: Nature Communications

Pavel M, Renna M, Park SJ, Menzies FM, Ricketts T, Fullgrabe J, et al.

27 July 2018

Publication: The Lancet

Michael J Sweeting, Katya L Masconi, PhD, Edmund Jones, PhD, Pinar Ulug, PhD, Matthew J Glover, MSc, Prof Jonathan A Michaels, MChir, Prof Matthew J Bown, MD, Prof Janet T Powell, MD, Prof Simon G Thompson, DSc

26 July 2018

Summary:

The NHS introduced ultrasound screening in men aged 65 and over in 2009 to detect and treat the condition – which arises when the main blood vessel swells in the abdomen, and is symptomless until the point of rupture. Since the launch, the programme has been successfully screening and identifying men at risk of an AAA.

Researchers wanted to see if UK women – who are less likely to have AAAs – could also benefit from a similar screening programme. Read the full press release here

Publication: International Journal of Obesity

Tarp J, Child A, White T, Westgate K, Bugge A, Grontved A, et al.

13 July 2018

In this study the researchers wanted to determine the role of physical activity intensity and bout-duration in modulating associations between physical activity and cardiometabolic risk markers.

Cardiovascular disease accounted for 17.6 million deaths worldwide in 2016, making it the leading cause of non-communicable disease mortality. While the disease is generally a concern in adulthood, cardiometabolic risk factors may be present from a much earlier age, for example endothelial damage that leads to atherosclerosis can develop during adolescence. In addition, previous evidence suggests cardiometabolic risk factors may track from childhood and adolescence into adulthood. This makes it important to understand the modifiable determinants of cardiometabolic risk factors in young people. One such determinant is participation in physical activity.

Current national and international physical activity guidelines recommend adults should accumulate moderate-to-vigorous physical activity (MVPA) or vigorous physical activity in bouts of at least 10 min duration. For children and adolescents, a daily total of at least 60 min of MVPA is recommended but many countries (including the U.S., U.K., Australia, and Canada) do not specify any minimum bout-duration for MVPA.

Providing the optimal guidance on how to perform health-enhancing physical activity is important for authorities and clinicians. However, whether short bouts of activity confer similar benefits to longer durations remains unclear and available evidence on this issue remains scarce in young people. Accelerometry is currently the de facto standard of objective physical activity assessment in large-scale epidemiological studies. It is well-established that accelerometry-determined MVPA levels are highly influenced by the choice of intensity threshold but it has not been sufficiently explored how varying the intensity threshold impacts on associations with cardiometabolic risk factors.

Further, whether higher (or lower) intensity physical activity may be particularly beneficial for cardiometabolic risk factors at longer bout-durations has yet to be examined.

Therefore, the purpose of this study was to assess how physical activity of different intensities and accumulated in bouts of varying duration relates to cardiometabolic health in young people.

Publication: Brain

Sami S, Williams N, Hughes LE, Cope TE, Rittman T, Coyle-Gilchrist ITS, et al.

9 July 2018

Publication: Brain

Hughes LE, Rittman T, Robbins TW, Rowe JB.

9 July 2018

Publication: The Journal of Hospital Infection

Wilson HJ, Khokhar F, Enoch DA, Brown NM, Ahluwalia J, Dougan G, et al.

2 July 2018

Publication: International Journal of Behavioral Nutrition and Physical Activity

Alessandra Prioreschi, Soren Brage, Kate Westgate & Lisa K. Micklesfield

25 June 2018

Summary

Evidence for the importance of accumulating sufficient physical activity in the early years is mounting. This study aimed to determine the relationship between maternal and infant objectively measured physical activity, and to examine the diurnal interactions between these behaviours while accounting for potential covariates.

Publication: Genome Biology

Sanders FWB, Acharjee A, Walker C, Marney L, Roberts LD, Imamura F, et al.

20 June 2018

Publication: The Lancet

Gemma D Banham, MRCP(UK), Shaun M Flint, FRACP,  Nicholas Torpey, FRCP, Paul A Lyons, PhD, Don N Shanahan, MSc, Adele Gibson, BSc, Prof Christopher J E Watson, FRCS, Ann-Marie O’Sullivan, MRes, Joseph A Chadwick, Katie E Foster, PhD, Rachel B Jones, FRCP, Luke R Devey, MRCSEd, Anna Richards, MRCP(UK), Prof Lars-Peter Erwig, MD, Prof Caroline O Savage,FMedSci, Prof Kenneth G C Smith, FMedSci, Robert B Henderson, PhD, Menna R Clatworthy, FRCP†

14 June 2018

Summary:

Transplantation is the best form of treatment for most patients with end-stage renal failure, but long-term graft survival is limited by the development of antibodies against the graft. There is therefore a major unmet need to find immunosuppressants that target humoral alloimmunity.

Researchers investigated the use of Belimumab, a monoclonal antibody that binds the B cell pro-survival cytokine BAFF, in kidney transplant recipients.

The study found that the use of belimumab was not associated with any excess risk of infection, and led to a reduction in antibody-producing plasmablasts, activated memory B cells, new IgG antibody formation and in non-HLA IgG antibodies associated with poor graft outcomes. Remarkably, belimumab treatment spared regulatory B cells – a cell type associated with transplant tolerance, with an increase in IL10-producing B cells observed.

Publication: Nature Genetics

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Dominguez MG, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA; Profile Study, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA.

11 June 2018

Publication: Nature Communications

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z. F

11 June 2018

Publication: Lung Cancer

Matys T, Drury R, David S, Rassl DM, Qian W, Rintoul RC, et al. Corrigendum to

10 June 2018

Publication: Nature

Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al.

6 June 2018

Publication: Pediatric Nephrology

Martin JL, Gruszczyk AV, Beach TE, Murphy MP, Saeb-Parsy K.

2 June 2018

Publication: The Lancet Haemotology

Lane WJ, Westhoff CM, Gleadall NS, Aguad M, Smeland-Wagman R, Vege S, et al.

1 June 2018

Publication: Psychoneuroendocrinology

Osimo EF, Cardinal RN, Jones PB, Khandaker GM.

May 2018

Publication: Best Practice & Research Clinical Obstetrics & Gynaecology

Smith GCS. Best Pract Res Clin Obstet Gynaecol.

May 2018

Publication: Nature

Barker RA, Gotz M, Parmar M.

16 May 2018

Publication: Nature Communications

Iglesias AI, Mishra A, Vitart V, Bykhovskaya Y, Hohn R, Springelkamp H, et al.

14 May 2018